2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
402
Colorectal Neoplasms
317
Rectal Neoplasms
235
Stomach Neoplasms
209
Pancreatic Neoplasms
137
Neoplasm Metastasis
123
Colonic Neoplasms
94
Neoplasms
86
Triple Negative Breast Neoplasms
64
Esophageal Neoplasms
57
Biliary Tract Neoplasms
39
Nasopharyngeal Carcinoma
37
Cholangiocarcinoma
31
Adenocarcinoma
31
Carcinoma, Hepatocellular
30
Gallbladder Neoplasms
29
Carcinoma, Non-Small-Cell Lung
21
Bile Duct Neoplasms
21
Locally Advanced Rectal Cancer
20
Adenocarcinoma Of Esophagus
20
Squamous Cell Carcinoma of Head and Neck
19
Brain Neoplasms
19
Gastrointestinal Neoplasms
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
17
Liver Neoplasms
17
Head and Neck Neoplasms
17
Esophageal Squamous Cell Carcinoma
17
Colorectal Cancer Metastatic
15
Ovarian Neoplasms
14
Breast Neoplasms, Male
14
Interventions
HhAntag691
25
Imiquimod
12
Biopsy
12
sonidegib
11
Aminolevulinic Acid
9
cemiplimab
8
Photochemotherapy
8
Nivolumab
8
methyl 5-aminolevulinate
7
Mohs Surgery
7
1-phenyl-3,3-dimethyltriazene
7
Tomography, Optical Coherence
6
Surgical Procedures, Operative
6
Specimen Handling
5
Radiotherapy
5
Itraconazole
5
pembrolizumab
4
daromun
4
Microscopy, Confocal
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Curettage
4
Standard of Care
3
Niacinamide
3
IPI-926
3
CTLA-4 Antigen
3
3-ingenyl angelate
3
tazarotene
2
talimogene laherparepvec
2
relatlimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Basal Cell
×
Capecitabine
×
Clear all
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled